administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: April 17, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–9889 Filed 4–20–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93N–0005]

Regulation of Positron Emission Tomography Radiopharmaceutical Drug Products; Guidance; Public Workshop; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of February 27, 1995 (60 FR 10594). The document published guidance on the regulation of positron emission tomography (PET) radiopharmaceutical drug products and announced a public workshop to facilitate an understanding of regulatory requirements regarding these products. The document was published with some typographical errors. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: LaJuana D. Caldwell, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2994.

In FR Doc. 95–4691, appearing on page 10594 in the **Federal Register** of February 27, 1995, the following corrections are made:

1. On page 10594, in the third column, in the title heading, ''TomographyRadiopharmaceutical'' is corrected to read ''Tomography Radiopharmaceutical''.

2. On page 10595, in the third column, in the third full paragraph, in the 4th line from the bottom, ''§ 1A207.10'' is corrected to read ''§ 207.10''.

3. On page 10596, in the first column, in the first full paragraph, in line 8, ''§ 1A361.1'' is corrected to read ''§ 361.1''.

4. On page 10596, in the first column, in the second paragraph, in lines 4 and 20, ''§ 1A361.1(c)'' is corrected to read ''§ 361.1(c)''.

5. On page 10596, in the second column, in the first full paragraph, in line 3, ''§ 1A361.1(c)(3)'' is corrected to read ''§ 361.1(c)(3)''.

Dated: April 14, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–9844 Filed 4–20–95; 8:45 am]

BILLING CODE 4160–01–F

SOCIAL SECURITY ADMINISTRATION

Agency Forms Submitted to the Office of Management and Budget for Clearance

Normally on Fridays, the Social Security Administration publishes a list of information collection packages that have been submitted to the Office of Management and Budget (OMB) for clearance in compliance with Public Law 96–511, The Paperwork Reduction Act. The following clearance packages have been submitted to OMB since the last list was published in the **Federal Register** on Friday, April 7, 1995.

(Call Reports Clearance Officer on (410) 965–4142 for copies of package.)

1. Measuring Public Perception of the Value of Social Security—0960–0551. The information on these questionnaires is used by the Social Security Administration (SSA) to measure public perception of the value of Social Security and to determine whether the Personal Earnings and Benefit Statement (PEBES) affects public confidence in Social Security. The control group respondents are members of the general public who have not received an SSA-initiated PEBES. The study group respondents are members of the general public who have received recently an SSA-initiated PEBES.

SSA has requested and received expedited approval for this collection of information (both the study group collection instrument and the control group collection instrument) from OMB and is, accordingly, publishing in the **Federal Register** a copy of each of the collection instruments (5 CFR 1320.18(g)).

Number of Respondents: 6,000
Frequency of Response: 1
Average Burden Per Response: 15 minutes
Estimated Annual Burden: 1,500 hours
OMB Desk Officer: Laura Oliven

Written comments and recommendations regarding these information collections should be sent directly to the appropriate OMB Desk Officer designated above at the following address: Office of Management and Budget, OIRA, New Executive Office Building, Room 10230, Washington, DC 20503.

Dated: April 17, 1995.

Charlotte Whitenight,

Reports Clearance Officer, Social Security Administration.

Measuring Public Perception of the Value of Social Security (Control Group)

Your Name _____

Your Social Security Number _____-____-_____

1. Are you aware that Social Security pays benefits (circle all that you are aware of):
   a. To you when you retire?
   b. To you if you became disabled?
   c. To your spouse if you became disabled or retired?
   d. To your young children if you became disabled or retired?
   e. To your widow if you should die?
   f. To your young children should you die?
2. How important is it for you to plan financially for your retirement?
   a. Very important
   b. Somewhat important